Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 5Neoplasms, Basal Cell 1Localized Pancreatic Adenocarcinoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Fluorouracil 8Oxaliplatin 7Leucovorin 6Irinotecan 6Gemcitabine 5fludarabine 3aldesleukin 3Pemetrexed 3Nivolumab 3Cyclophosphamide 3Cetuximab 3Capecitabine 35,10-methylenetetrahydrofolic acid 3dehydroftorafur 2cobimetinib 2Specimen Handling 2Panitumumab 2Interleukin-2 2Docetaxel 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tivozanib 1sodium propionate 1rucaparib 1rilotumumab 1repotrectinib 1regorafenib 1pralsetinib 1pertuzumab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gastrointestinal Neoplasms × folfirinox × Clear all
NCT05121038 2024-12-17

CENDIFOX

University of Kansas Medical Center

Phase 1/2 Active not recruiting
50 enrolled
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡